Viracta Therapeutics to Present at RBC Healthcare Conference

SAN DIEGO, May 07, 2024 – Viracta Therapeutics, Inc. (Nasdaq: VIRX), a company engaged in precision oncology targeting virus-associated cancers, announced that its key executives will be participating in the RBC Capital Markets Global Healthcare Conference. Mark Rothera, the President and CEO, along with Dr. Darrel P. Cohen, the Chief Medical Officer, are scheduled to engage in a fireside chat on Tuesday, May 14, 2024, at 11:00 a.m. EDT. The presentation will be webcast live and made available on the Investors section of Viracta’s website under "Events and Webcasts," where it will also be archived for 90 days.

Viracta Therapeutics is at the forefront of developing treatments for cancers linked to viral infections. Their primary focus is on a combination therapy named Nana-val, which includes the investigational drug nanatinostat and the antiviral agent valganciclovir. This all-oral therapy is undergoing extensive clinical trials aimed at treating various subtypes of Epstein-Barr virus-positive (EBV+) lymphoma and other related diseases.

Nana-val is being tested in several ongoing clinical trials, one of which is a pivotal, global, multicenter, open-label Phase 2 basket trial (NAVAL-1). This trial targets multiple subtypes of relapsed or refractory (R/R) EBV+ lymphomas. Additionally, a multinational, open-label Phase 1b/2 clinical trial is also in progress. This trial is focused on patients with recurrent or metastatic (R/M) EBV+ nasopharyngeal carcinoma (NPC) and other advanced EBV+ solid tumors.

Beyond these trials, Viracta is exploring its unique “Kick and Kill” approach for other EBV-related diseases. This innovative method aims to activate the virus within the cancer cells and subsequently destroy those cells, providing a targeted treatment strategy.

Viracta remains committed to advancing its research and expanding its therapeutic arsenal for virus-associated cancers. The company’s participation in the RBC Capital Markets Global Healthcare Conference reflects its ongoing efforts to engage with the broader medical and investment communities, sharing updates on its progress and future plans.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!